Thorax

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spiro, S G
Right arrow Articles by Rudd, R M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spiro, S G
Right arrow Articles by Rudd, R M
Thorax 2000;55:463-465 ( June )

Recruitment of patients with lung cancer into a randomised clinical trial: experience at two centres

S G Spiroa, N H Gowera b, M T Evansb, F M Facchinia, R M Ruddb, on behalf of the Big Lung Trial Steering Committee

a Department of Thoracic Medicine, University College London Hospitals NHS Trust, London, UK, b Department of Medical Oncology, St Bartholomew's and The London NHS Trust, London, UK

Correspondence to: N H Gower, London Lung Cancer Group, CRC and UCL Cancer Trials Centre, RF and UC Medical School, John Astor House, Foley Street, London W1P 8AN, UK email: n.gower{at}ctc.ucl.ac.uk

Received 13 September 1999; Accepted for publication 22 December 1999

BACKGROUND---The entry of patients into randomised clinical trials (RCTs) in lung cancer is low. A study was undertaken to assess the reasons why patients with non-small cell lung cancer did not enter a trial involving randomisation to receive or not receive three courses of cisplatin based chemotherapy in addition to primary treatment by surgery, radiotherapy, or best supportive care.
METHODS---The study was carried out in two large London institutions with a special interest in recruiting patients to lung cancer trials. Patients recently diagnosed as having non-small cell lung cancer were prospectively identified and followed to see whether they entered the RCT and, if not, to identify the main reasons why.
RESULTS---Six hundred and eighty eight patients newly diagnosed with non-small cell lung cancer were identified between November 1995 and July 1998; 274 (39.8%) were deemed ineligible for the RCT for clinical reasons, most frequently their general condition rendering them unfit for chemotherapy. Another 161 (23.4%) were ineligible for logistical reasons---for example, they were discharged to centres not participating in the RCT or they were not considered for the trial at an appropriate time in their management. Of 253 potentially eligible patients, only 63 (24.9% of those eligible) agreed to enter the RCT and four entered another study. Of those who did not enter, 77 (41.4%) declined without stating a reason, 61 (32.8%) did not want chemotherapy, and only eight (4.3%) expressed a wish to have chemotherapy.
CONCLUSIONS---Despite considerable time and effort, the proportion of patients recruited was small (9.2%). Many seen were ineligible but, of 253 potentially eligible patients, 186 (73.5%) refused to enter the RCT.


Keywords: lung cancer; chemotherapy; randomised controlled trials; patient recruitment

© 2000 by Thorax


This article has been cited by other articles:


Home page
 Postgrad. Med. J.Home page
G A Silvestri and S G Spiro
Carcinoma of the bronchus 60 years later
Postgrad. Med. J., April 1, 2008; 84(990): 182 - 187.
[Full Text] [PDF]

Home page
 ThoraxHome page
G A Silvestri and S G Spiro
Carcinoma of the bronchus 60 years later.
Thorax, December 1, 2006; 61(12): 1023 - 1028.
[Full Text] [PDF]

Home page
 JCOHome page
G. J.M. Herder, H. Kramer, O. S. Hoekstra, E. F. Smit, J. Pruim, H. van Tinteren, E. F. Comans, P. Verboom, C. A. Uyl-de Groot, A. Welling, et al.
Traditional Versus Up-Front [18F] Fluorodeoxyglucose-Positron Emission Tomography Staging of Non-Small-Cell Lung Cancer: A Dutch Cooperative Randomized Study
J. Clin. Oncol., April 20, 2006; 24(12): 1800 - 1806.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
S G Spiro, R M Rudd, R L Souhami, J Brown, D J Fairlamb, N H Gower, L Maslove, R Milroy, V Napp, M K B Parmar, et al.
Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life
Thorax, October 1, 2004; 59(10): 828 - 836.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S. G. Spiro and J. C. Porter
Lung Cancer--Where Are We Today?: Current Advances in Staging and Nonsurgical Treatment
Am. J. Respir. Crit. Care Med., November 1, 2002; 166(9): 1166 - 1196.
[Abstract] [Full Text] [PDF]

Home page
 DTBHome page
Chemotherapy and non-small-cell lung cancer
DTB, February 1, 2002; 40(2): 9 - 11.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
F. W. Grannis Jr
A response to ""Clinical Trials in Lung Cancer: Truth, Justice, and the American Way""
Ann. Thorac. Surg., October 1, 2001; 72(4): 1438 - 1438.
[Full Text] [PDF]

Home page
 ThoraxHome page
A. PRICE
Patient accrual into chemotherapy trials in non-small cell lung cancer
Thorax, June 1, 2000; 55(6): 447 - 448.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2000 BMJ Publishing Group Ltd & British Thoracic Society